Backgroud: Epilepsy is a chronic medical condition requiring long term or even lifelong therapy. Various researches have shown that epilepsy patients have vascular risk factors such as abnormal lipids, insulin, elevated oxidative stress, chronic inflammation, and subclinical atherosclerosis. Objectives: The purpose of the present study was to determine serum prolidase enzyme activity as a biomarker in children taking antiepileptic drug treatment through comparison with control cases. Materials and Methods: The present study group consists of 61 children (20 females, 41 males) with epilepsy and a control group was formed of 32 healthy individuals (14 females, 18 males). Aspectrophotometric method was used to measure serum prolidase enzyme activity. Results: The epilepsy group demonstrated statistically significantly higher prolidase enzyme activity values when compared with the control group (P = 0.003). It was measured that the serum TOS and OSI values were significantly elevated in patients with epilepsy compared to controls (P < 0.001). However, serum TAS values were significantly lower in the epilepsy group than in the control group (P = 0.032). Conclusions: These results supported that epileptic patients taking the antiepileptic treatment had increased serum prolidase enzyme activity, suggesting that it may show an increased risk of subclinical vascular damage related to both chronic inflammation and fibrotic process associated with degenerated collagen turnover. Therefore, serum prolidase enzyme activity could be considered a useful biomarker for evaluation of the subclinical vascular damage in children with epilepsy on some antiepileptic drugs.

中文翻译：

---

血清脯氨酸酶活性作为评估癫痫患儿亚临床血管损伤的生物标志物

背景：癫痫是一种需要长期甚至终生治疗的慢性疾病。多项研究表明，癫痫患者存在血脂异常、胰岛素异常、氧化应激升高、慢性炎症、亚临床动脉粥样硬化等血管危险因素。目的：本研究的目的是通过与对照病例的比较，确定接受抗癫痫药物治疗的儿童的血清脯氨酸酶活性作为生物标志物。材料与方法：本研究组由61名癫痫患儿（20名女性，41名男性）组成，对照组由32名健康个体（14名女性，18名男性）组成。采用分光光度法测定血清脯氨酸酶活性。结果：与对照组相比，癫痫组表现出统计学上显着更高的脯氨酸酶活性值（P = 0.003）。经测量，与对照组相比，癫痫患者的血清 TOS 和 OSI 值显着升高（P <0.001）。然而，癫痫组的血清TAS值显着低于对照组（P = 0.032）。结论：这些结果支持接受抗癫痫治疗的癫痫患者血清脯氨酸酶活性增加，这表明它可能显示出与慢性炎症和与退化的胶原更新相关的纤维化过程相关的亚临床血管损伤的风险增加。因此，血清脯氨酸酶活性可被认为是评估某些抗癫痫药物对癫痫患儿亚临床血管损伤的有用生物标志物。